Logo image of ENTG.CA

ENTOURAGE HEALTH CORP (ENTG.CA) Stock Fundamental Analysis

Canada - TSX-V:ENTG - CA2938611001 - Common Stock

0.005 CAD
0 (0%)
Last: 4/8/2025, 7:00:00 PM
Fundamental Rating

1

ENTG gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 31 industry peers in the Pharmaceuticals industry. ENTG may be in some trouble as it scores bad on both profitability and health. ENTG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ENTG has reported negative net income.
ENTG had a negative operating cash flow in the past year.
ENTG had negative earnings in each of the past 5 years.
ENTG had a negative operating cash flow in each of the past 5 years.
ENTG.CA Yearly Net Income VS EBIT VS OCF VS FCFENTG.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of ENTG (-170.85%) is worse than 88.89% of its industry peers.
Industry RankSector Rank
ROA -170.85%
ROE N/A
ROIC N/A
ROA(3y)-155.61%
ROA(5y)-104.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENTG.CA Yearly ROA, ROE, ROICENTG.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of ENTG (13.18%) is worse than 72.22% of its industry peers.
ENTG's Gross Margin has been stable in the last couple of years.
ENTG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.13%
ENTG.CA Yearly Profit, Operating, Gross MarginsENTG.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

ENTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ENTG has been increased compared to 1 year ago.
The number of shares outstanding for ENTG has been increased compared to 5 years ago.
ENTG has a worse debt/assets ratio than last year.
ENTG.CA Yearly Shares OutstandingENTG.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
ENTG.CA Yearly Total Debt VS Total AssetsENTG.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -30.71, we must say that ENTG is in the distress zone and has some risk of bankruptcy.
ENTG has a Altman-Z score of -30.71. This is amonst the worse of the industry: ENTG underperforms 91.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -30.71
ROIC/WACCN/A
WACC0.76%
ENTG.CA Yearly LT Debt VS Equity VS FCFENTG.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 0.10 indicates that ENTG may have some problems paying its short term obligations.
ENTG has a worse Current ratio (0.10) than 94.44% of its industry peers.
A Quick Ratio of 0.04 indicates that ENTG may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.04, ENTG is doing worse than 94.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.04
ENTG.CA Yearly Current Assets VS Current LiabilitesENTG.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

ENTG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.09%, which is quite impressive.
The Revenue has been growing slightly by 5.08% in the past year.
The Revenue has been growing by 38.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)64.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.53%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y11.42%
Revenue growth 5Y38.62%
Sales Q2Q%9.09%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTG.CA Yearly Revenue VS EstimatesENTG.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ENTG.CA Yearly EPS VS EstimatesENTG.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTG.CA Price Earnings VS Forward Price EarningsENTG.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTG.CA Per share dataENTG.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENTG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTOURAGE HEALTH CORP

TSX-V:ENTG (4/8/2025, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-28 2024-11-28
Earnings (Next)05-05 2025-05-05
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.54%
Ins Owner ChangeN/A
Market Cap1.53M
Revenue(TTM)41.46M
Net Income(TTM)-42.16M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.14
BVpS-0.56
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -170.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.18%
FCFM N/A
ROA(3y)-155.61%
ROA(5y)-104.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.13%
F-Score4
Asset Turnover1.68
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.24%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.04
Altman-Z -30.71
F-Score4
WACC0.76%
ROIC/WACCN/A
Cap/Depr(3y)116.21%
Cap/Depr(5y)4125%
Cap/Sales(3y)2.76%
Cap/Sales(5y)56.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.08%
Revenue growth 3Y11.42%
Revenue growth 5Y38.62%
Sales Q2Q%9.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.85%
OCF growth 3YN/A
OCF growth 5YN/A

ENTOURAGE HEALTH CORP / ENTG.CA FAQ

What is the ChartMill fundamental rating of ENTOURAGE HEALTH CORP (ENTG.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ENTG.CA.


What is the valuation status of ENTOURAGE HEALTH CORP (ENTG.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTOURAGE HEALTH CORP (ENTG.CA). This can be considered as Overvalued.


What is the profitability of ENTG stock?

ENTOURAGE HEALTH CORP (ENTG.CA) has a profitability rating of 0 / 10.